Surgical Treatment of Sleep Apnea and Snoring
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 1.128 alerts
Get alerted when Policy MP 1.128 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and investigational indications for surgical interventions for obstructive and central sleep apnea and snoring for Capital BlueCross products, and notes product-specific variations.
Phrenic nerve stimulation for central sleep apnea (CSA) has been added to the policy as investigational along with associated coding.
Criteria and formatting for OSA statements were changed and cross-references/background updated.
Adult hypoglossal nerve stimulation AHI allowance changed to ≤100 and pediatric age/BMI criteria were modified in prior reviews.
Coverage Criteria and Medical Necessity
Palatopharyngoplasty (Adults)
Covered when ALL of the following are met:
Procedures listed: uvulopalatopharyngoplasty, uvulopharyngoplasty, uvulopalatal flap, expansion sphincter pharyngoplasty, lateral pharyngoplasty, palatal advancement pharyngoplasty, relocation pharyngoplasty.
Hypopharyngeal-targeted surgeries (Adults)
Covered when ALL of the following are met:
Includes mandibular-maxillary advancement (MMA), hyoid suspension, surgical modification of the tongue.
Adenotonsillectomy (Pediatrics)
Covered when ALL of the following are met:
Pediatric population specified.
Hypoglossal nerve stimulation (Adults)
Covered when ALL of the following are met for adults:
Device-specific indications (Inspire) referenced.
Hypoglossal nerve stimulation (Adolescents with Down syndrome)
Covered when ALL of the following are met:
Specific to Down syndrome adolescents/young adults.
Investigational / Not Medically Necessary Procedures
Procedures considered investigational (Not covered):
These procedures are investigational due to insufficient evidence.
Coverage by intervention
Coverage stance is split by intervention and indication:
Although clinical trials exist, policy lists phrenic nerve stimulation as investigational.
Coverage depends on the specific procedure code as listed in policy.
Supports step therapy prior to implantation.
Hypoglossal nerve stimulation — selection guidance
HNS may be appropriate in select patients who meet study-based selection criteria:
Derived from clinical trial selection criteria and clinical input; policy notes variability in study cutoffs.
Policy-level coverage statements and historical modifications
Added with associated coding per 01/22/2025 update.
Multiple policy history entries document these changes.
The policy lists a group of minimally invasive palatal and tongue procedures that are regarded as investigational because current evidence does not demonstrate a clear net health benefit. Examples include laser-assisted palatoplasty, radiofrequency volumetric tissue reduction of the palate, radiofrequency volumetric reduction of the tongue (with or without palatal RF), palatal stiffening procedures (for example, cautery-assisted palatal stiffening, injection of sclerosing agents, and palatal implants), tongue base suspension, and other similar minimally invasive techniques. These interventions are also considered investigational when used to treat isolated snoring in the absence of documented obstructive sleep apnea.
Phrenic nerve stimulation for the treatment of central sleep apnea (CSA) is designated investigational in all situations by this policy. Although clinical trials and observational studies are described in the evidence base, the policy was updated to add an investigational statement and associated coding for phrenic nerve stimulation (see policy history entries).
The policy explicitly lists procedure and device codes that are categorized as Investigational; therefore, not covered. Examples provided in the policy coding tables include codes associated with investigational surgical treatments for OSA such as 41512, 41530, 42299, C9727, S2080, and codes associated with investigational phrenic nerve stimulation for CSA such as 93150, 33277–33281, 33287–33288 and related HCPCS entries. Providers should refer to the coding tables in the policy when determining coverage vs investigational status for a specific billed code.
Per the policy history, procedure code 41512 has been moved to the noncovered coding table (not medically necessary / noncovered). This coding relocation is documented in the 01/22/2025 update and reflected in the policy coding tables.
Minimally invasive palatal and tongue procedures — including laser-assisted palatoplasty, radiofrequency volumetric tissue reduction of the palate or tongue, palatal stiffening procedures (cautery-assisted stiffening, sclerosing injections, palatal implants), and tongue base suspension — are considered investigational and therefore not medically necessary when criteria for medical necessity are not met. The policy notes insufficient evidence of clinically meaningful improvement in outcomes for these techniques.
The policy summarizes that evidence is insufficient for many minimally invasive procedures and some device-based therapies. For example, single RCTs and small trials of laser-assisted uvulopalatoplasty and various radiofrequency palatal procedures have shown limited or inconsistent effects on AHI and symptoms. Palatal stiffening trials yielded mixed results across RCTs, and tongue base suspension is supported only by small feasibility trials. Overall, the body of evidence is judged inadequate to establish improvement in net health outcomes for these listed procedures.
The policy history documents that on 01/22/2025 phrenic nerve stimulation for central sleep apnea was added to the policy as investigational with associated coding changes. This administrative update explicitly classifies phrenic nerve stimulation for CSA as investigational (not covered).
Coding and Identifiers
| K982717 | Radiofrequency ablation 510(k) number (Somnoplasty) |
| K040417 | Palatal Implant 510(k) number (Pillar Palatal Implant) |
| K122391 | Tongue base suspension 510(k) number (AIRvance) |
| K111179 | Tongue base suspension 510(k) number (Encore/PRELUDE III) |
| P130008 | Inspire hypoglossal nerve stimulation PMA/IDE identifier |
| 41512 | Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA' |
| 41530 | Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA' |
| 42299 | Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA' |
| C9727 | Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA' |
| S2080 | Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA' |
| 93150 | Listed under 'Investigational; therefore, not covered: Phrenic Nerve Stimulation for Central Sleep Apnea' |
| 33277 | Procedure code variant listed under investigational phrenic nerve stimulation |
| 33278 | Procedure code variant listed under investigational phrenic nerve stimulation |
| 33279 | Procedure code variant listed under investigational phrenic nerve stimulation |
| 33280 | Procedure code variant listed under investigational phrenic nerve stimulation |
| 33281 | Procedure code variant listed under investigational phrenic nerve stimulation |
| 33287 | Procedure code variant listed under investigational phrenic nerve stimulation |
| 33288 | Procedure code variant listed under investigational phrenic nerve stimulation |
| C1823 | HCPCS code listed in the phrenic nerve stimulation group |
| 42826 | Procedure code listed under 'Covered when medically necessary: Surgical Treatments for OSA' |
| 21685 | Procedure code variant listed under covered surgical treatments |
| 41120 | Procedure code variant listed under covered surgical treatments |
| 41130 | Procedure code variant listed under covered surgical treatments |
| 41599 | Procedure code variant listed under covered surgical treatments |
| 42145 | Procedure code variant listed under covered surgical treatments |
| 42820 | Procedure code variant listed under covered surgical treatments |
| 42821 | Procedure code variant listed under covered surgical treatments |
| 42825 | Procedure code variant listed under covered surgical treatments |
| 64568 | Procedure code (asterisked) listed under covered surgical treatments |
| MP 1.128 | Policy number referenced in coding history and updates |
| 41512 | Procedure code mentioned as moved to noncovered and earlier MN |
| 42975 | Procedure code previously added then later removed from policy |
| 64582-64584 | Codes added in 12/01/2021 Administrative Update |
| 0466T-0468T | Codes deleted in 12/01/2021 Administrative Update |
| 21299 | Procedure code added then later removed per 01/22/2025 |
| 31600 | Procedure code added then later removed per 01/22/2025 |
| 31601 | Procedure code added then later removed per 01/22/2025 |
| 41120 | Procedure code added earlier per policy history |
| 41130 | Procedure code added earlier per policy history |
| 42830-31 | Procedure codes added earlier per policy history |
Provider Responsibilities, Authorization, and Documentation
Prior Trial Requirement
Prior trial requirement: A prior trial and failure or intolerance of continuous positive airway pressure (CPAP) — or an adequate trial of an oral appliance where specified — is required before many surgical therapies for obstructive sleep apnea (OSA) will be considered medically necessary. Documentation should include objective sleep study results (AHI or RDI) and evidence that the member either failed CPAP (residual AHI ≥15 or inability/unwillingness to use CPAP ≥4 hours/night for ≥5 nights/week) or failed/intolerant of an oral appliance when applicable.
- CPAP is preferred first-line therapy for most patients; oral appliances may be first-line for a smaller number of patients.
- Prior CPAP failure may be defined as residual AHI ≥15 or insufficient use (≥4 hrs/night for ≥5 nights/week) or intolerance.
First-line Therapy Precedence
First-line therapy precedence: Continuous positive airway pressure (CPAP) is the preferred first-line treatment for most patients with sleep-disordered breathing. Oral appliances are an alternative first-line option for a subset of patients; surgical or invasive interventions are generally considered only after adequate trials of noninvasive therapies have failed.
- Noninvasive options include CPAP, oral appliance therapy, supplemental oxygen, bilevel PAP, and adaptive servo-ventilation (ASV) where clinically appropriate.
- ASV has specific contraindications (e.g., increased CV mortality in CSA with heart failure and EF <45%).
Consideration After Failure of Non-surgical Therapy
Consideration after failure of non-surgical therapy: Invasive procedures (including surgical treatments and implantable devices) are typically considered only after failure of appropriate non-surgical treatments. For some technologies (e.g., phrenic nerve stimulation for CSA), limited data exist in patients who have failed standard-of-care noninvasive therapies.
- Ensure documentation of prior noninvasive treatments tried and reasons for failure or intolerance.
- Devices or procedures with limited evidence in post–noninvasive-failure populations may remain investigational.
Investigational Procedures — Denial Risk
Investigational items denial risk: Procedures or devices that the policy designates as investigational (not supported by sufficient evidence) are not covered and may be denied if billed as covered services.
- Examples include phrenic nerve stimulation for central sleep apnea (listed investigational) and other surgical treatments explicitly listed as investigational in the coding table.
- Surgical treatment of OSA that does not meet the policy’s medical necessity criteria (e.g., HNS outside specified indications) is considered investigational and likely to be denied.
Coding and Coverage Documentation
Listed procedure and diagnosis codes: A policy-specific coding table exists; however, the list of codes may not be all-inclusive and is subject to change. The presence of a code in the coding section does not by itself indicate coverage — coverage is determined by matching the billed code to the clinical and medical necessity criteria in this policy.
- All billing must be matched to the current coding table and the policy’s coverage status for that code (covered, not covered/investigational).
- ICD-10 diagnosis code G47.33 (Obstructive sleep apnea) is the primary diagnosis driving these procedures; other ICD-10 codes were removed per recent coding updates.
Authorization Must Match Current Policy Criteria
Authorization must match current policy criteria: Prior authorization, when required, must reflect the current medical necessity criteria and coding status in this policy. Requests that do not document required objective testing, prior therapy trials, or that propose investigational procedures will not meet criteria for authorization.
- Authorization requests must include objective sleep study indices (AHI or RDI) and documentation of prior adequate trials of CPAP or oral appliance where applicable.
- Providers should verify that the requested procedure code’s coverage status in the latest coding table aligns with the clinical indication and policy criteria.
Background and Context
Obstructive sleep apnea (OSA) is characterized by repetitive upper airway collapse during sleep, leading to hypoxemia, fragmented sleep, and excessive daytime sleepiness. OSA is associated with cardiovascular and neurocognitive consequences, which motivates treatment when clinically significant (commonly defined by indices such as the Apnea–Hypopnea Index (AHI)). Surgical and device-based therapies aim to reduce airway collapse or stabilize respiratory drive; selection of invasive therapies is typically reserved for patients with documented OSA who have failed or are intolerant of first-line noninvasive therapies (for example, continuous positive airway pressure). The policy distinguishes OSA from central sleep apnea (CSA), the latter involving reduced ventilatory drive and for which different therapies, including phrenic nerve stimulation in trials, have been evaluated but are here classified investigational.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.